



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of

75

**Complete if Known**

Application Number	09/509,734
Filing Date	06/14/2000
First Named Inventor	Iltescu, S.
Group Art Unit	1644
Examiner Name	David A. Saunders
Attorney Docket Number	A31856-PCT-USA

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>Self</i>	12	Rizeq, M., Masek, M.A., and Billingham, M.E. Acute rejection: significance of elapsed time after transplantation. The Journal of Heart and Lung Transplantation. 1994; 13(5); 862-868	
	13	Winters, G.L., Loh, E., Schoen, F.J., Natural history of focal moderate cardiac allograft rejection: is treatment warranted. Circulation. 1995; 91:1975-1980.	
	14	White J.A., Guirandon C., Pflugfelder P.W., Kostuk W.J. Routine surveillance myocardial biopsies are unnecessary beyond one year after heart transplantation. The Journal of Heart and Lung Transplantation 1995; 14:1052.	
	15	Smith, J.D., Danskin, A.J., Laylor, R.M., Rose, M.L., and Yacoub, M.H. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transplant Immunology 1993; 1:60-65.	
	16	Rose, E.A., Smith, C.R., Petrossian, G.A., Barr, M.L., Reemtsma, K. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery 1989; 106:203-208.	
	17	Kemkes, B.M., Schultz, A., Engelhardt, M., Brandl, U., and Breuer, M. Noninvasive methods of rejection diagnosis after heart transplantation. The Journal of Heart and Lung Transplantation 1992; 11:S221-S231.	
	18	Hall T., Baumgartner W., Borkin A., et al. Diagnosis of acute cardiac rejection with antimyosin antibody monoclonal antibody, phosphorus nuclear magnetic imaging, two dimensional echocardiography and endocardial biopsy. The Journal of Heart Transplantation 1986; 6:419-24.	
	19	Wisenberg G., Pflugfelder J.V., Kostuk, W.J., McKenzie F.N., Prato F.S. Diagnostic applicability of magnetic resonance imaging in assessing human cardiac allograft rejection. American Journal of Cardiology 1987; 53:130.	
	20	George, J.F., Kirklin, J.K., Shroyer, T.W., et al. Utility of a posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients. The Journal of Heart and Lung Transplantation 1995; 14:856-864.	
	21	Smith, J.D., Danskin, A.J., Rose, M.L., and Yacoub, M.H. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. Transplantation 1992; 53:1358-62	
	22	Zavazava, N., Botcher, H., and Ruchholtz, W.M., Soluble MHC Class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 1993; 42:20-26.	

Examiner  
Signature*David A. Saunders*Date  
Considered*8/6/03*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

TECH CENTER 1600/2900

DEC 20 2002

RECEIVED